VNDA
Vanda Pharmaceuticals Inc.
$4.75
+$0.26(+5.79%)
52
Overall
60
Value
45
Tech
--
Quality
Market Cap
$265.31M
Volume
468.27K
52W Range
$3.81 - $5.55
Target Price
$12.67
Order:
Income Statement
| Metric | Trend | Chart | 2015 Dec | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $109.9M | $292.0M | $165.1M | $193.1M | $227.2M | $248.2M | $268.7M | $254.4M | $192.6M | $198.8M | ||
| Total Revenue | $109.9M | $146.0M | $165.1M | $193.1M | $227.2M | $248.2M | $268.7M | $254.4M | $192.6M | $198.8M | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | $23.5M | $24.7M | $17.8M | $20.5M | $24.5M | $23.4M | $25.6M | $24.3M | $14.8M | $11.3M | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $86.5M | $267.3M | $147.2M | $172.6M | $202.7M | $224.8M | $243.1M | $230.1M | $177.8M | $187.5M | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $126.6M | $139.9M | $164.1M | $150.9M | $179.9M | $197.6M | $200.9M | $223.8M | $191.8M | $228.1M | ||
| Research & Development | $29.1M | $29.2M | $38.5M | $43.6M | $48.6M | $55.6M | $75.4M | $85.8M | $76.8M | $74.4M | ||
| Research Expense | $29.1M | $29.2M | $38.5M | $43.6M | $48.6M | $55.6M | $75.4M | $85.8M | $76.8M | $74.4M | ||
| Selling, General & Administrative | $84.5M | $99.8M | $123.8M | $105.8M | $129.7M | $140.5M | $124.0M | $136.5M | $112.9M | $146.4M | ||
| Selling & Marketing Expenses | $84.5M | $99.8M | $123.8M | $105.8M | $3.2M | $12.6M | $6.7M | $2.6M | $500.0K | $1.9M | ||
| General & Administrative Expenses | $-1.9M | $-2.5M | $-3.2M | $-3.6M | $129.7M | $140.5M | $124.0M | $136.5M | $112.9M | $146.4M | ||
| Promotion & Advertising | $-3.4M | $-1.4M | $-1.3M | $-900.0K | $3.2M | $12.6M | $6.7M | $2.6M | $500.0K | $1.9M | ||
| Salaries & Wages | $-8.0M | $-8.5M | $-10.5M | $-11.7M | -- | -- | -- | $16.3M | $14.0M | $12.4M | ||
| Depreciation & Amortization | $13.0M | $10.9M | $1.8M | $1.5M | $1.5M | $1.5M | $1.5M | $1.5M | $2.1M | $7.3M | ||
| Depreciation & Amortization | $13.0M | $10.9M | $1.8M | $1.5M | $1.5M | $1.5M | $1.5M | $1.5M | $2.1M | $7.3M | ||
| Amortization | $13.0M | $10.9M | $1.8M | $1.5M | $1.5M | $1.5M | $1.5M | $1.5M | $2.1M | $7.3M | ||
| Other Operating Expenses | -- | -- | -- | -- | $-1.5M | $-1.6M | $-1.6M | $-2.9M | $-2.0M | $-742.0K | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-40.2M | $127.4M | $-16.9M | $21.7M | $22.8M | $27.2M | $42.2M | $6.3M | $-14.0M | $-40.7M | ||
| EBITDA | $-26.3M | $-6.0M | $-12.4M | $28.3M | $31.9M | $30.1M | $45.0M | $14.0M | $9.3M | $-14.7M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | -- | -- | -- | -- | -- | -- | -- | -- | -- | $32.0K | ||
| Net Non-Operating Interest Income/Expense | -- | -- | -- | -- | -- | -- | -- | -- | -- | $-32.0K | ||
| Other Income/Expense | $-320.0K | $-665.0K | $-1.5M | $-3.6M | $-6.2M | $-4.4M | $-199.0K | $5.0M | $-20.3M | $-17.7M | ||
| Other Special Charges | $320.0K | $665.0K | $1.5M | $3.6M | $6.2M | $4.4M | $199.0K | $5.0M | $20.3M | $17.7M | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-39.9M | $-17.9M | $-15.4M | $25.3M | $29.0M | $27.2M | $42.2M | $11.3M | $6.3M | $-22.9M | ||
| Pre-Tax Income | $-39.9M | $-17.9M | $-15.4M | $25.3M | $29.0M | $31.7M | $42.4M | $11.3M | $6.3M | $-22.9M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | -- | $104.0K | $100.0K | $138.0K | $-86.5M | $8.3M | $9.2M | $5.0M | $3.8M | $-4.0M | ||
| NET INCOME | ||||||||||||
| Net Income | $-39.9M | $128.0M | $-15.5M | $25.2M | $115.6M | $23.3M | $33.2M | $6.3M | $2.5M | $-18.9M | ||
| Net Income (Continuing Operations) | $-39.9M | $128.0M | $-15.5M | $25.2M | $115.6M | $23.3M | $33.2M | $6.3M | $2.5M | $-18.9M | ||
| Net Income (Discontinued Operations) | $-39.9M | $128.0M | $-15.5M | $25.2M | $115.6M | $23.3M | $33.2M | $6.3M | $2.5M | $-18.9M | ||
| Net Income (Common Stockholders) | $-39.9M | $128.0M | $-15.5M | $25.2M | $115.6M | $23.3M | $33.2M | $6.3M | $2.5M | $-18.9M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | -- | -- | -- | $-26.9M | ||
| TOTALS | ||||||||||||
| Total Expenses | $150.1M | $164.6M | $182.0M | $171.4M | $204.4M | $220.9M | $226.5M | $248.1M | $206.6M | $239.4M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $42.3M | $43.4M | $44.7M | $50.9M | $53.1M | $54.4M | $55.5M | $56.5M | $57.4M | $58.1M | ||
| Average Shares Outstanding (Diluted) | $42.3M | $43.4M | $44.7M | $53.0M | $54.8M | $55.2M | $56.9M | $57.0M | $57.6M | $58.1M | ||
| Shares Outstanding | $43.1M | $44.3M | $45.4M | $52.6M | $53.6M | $54.9M | $55.9M | $56.8M | $57.5M | $58.3M | ||
| Basic EPS | $-0.94 | $-0.41 | $-0.35 | $0.50 | $2.17 | $0.43 | $0.60 | $0.11 | $0.04 | $-0.33 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | -- | $2.17 | $0.43 | $0.60 | $0.11 | $0.04 | $-0.33 | ||
| Diluted EPS | $-0.94 | $-0.41 | $-0.35 | $0.48 | $2.11 | $0.42 | $0.58 | $0.11 | $0.04 | $-0.33 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | $2.11 | $0.42 | $0.58 | $0.11 | $0.04 | $-0.33 | ||
| OTHER METRICS | ||||||||||||
| Other Gand A | $-1.9M | $-2.5M | $-3.2M | $-3.6M | $129.7M | $140.5M | $124.0M | $136.5M | $112.9M | $146.4M | ||
| Rent And Landing Fees | $-1.9M | $-2.5M | $-3.2M | $-3.6M | -- | -- | -- | -- | -- | -- | ||
| Selling Expense | $84.5M | $99.8M | $123.8M | $105.8M | -- | -- | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | VNDA | $4.75 | +5.8% | 468.27K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Vanda Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW